The expression profiling of serum miR-92a, miR-134 and miR-375 in acute ischemic stroke

Plain language summaryThis study aimed to examine how miR-92a, 134, and 375 in acute ischemic stroke (AIS) patients were expressed and if they could be used to diagnose the disease. Hence, their expression profiles were assessed in the serum of 70 AIS patients and 25 controls. Results showed that miR-92a and miR-375 were downregulated, while miR-134 was mostly upregulated. miR-92a and miR-375 had the best diagnostic accuracy, but miR-375 was more specific. Therefore, miR-92a and miR-375 show promise as potential early AIS biomarkers. Aim: To investigate the expression profile and diagnostic potentials of serum miR-92a, 134, and 375 in acute ischemic stroke (AIS) patients. Materials & methods: Serum miRs-92a, 134, and 375 expression profiles were estimated by qRT-PCR for 70 AIS patients, age-matched with 25 control subjects. Their diagnostic potential was estimated by ROC analysis. Results: Down-expression of miR-92a and miR-375 was found (56; 96.5%; -1.86 +/- 1.36; and 53; 91.4%; -1.63 +/- 1.38, respectively), while miR-134 showed a predominant upregulation (46; 79.3%; 0.853 +/- 1.34). The diagnostic accuracy was the highest for miR-92a and miR-375 (area under the curve = 0.9183 and 0.898, respectively), with greater specificity for miR-375 (Sp = 96%). Conclusion: Serum miR-92a and miR-375 could be promising early detective biomarkers of AIS.

Automated summary

This study aimed to investigate the expression profile and diagnostic potential of serum miR-92a, 134, and 375 in acute ischemic stroke (AIS) patients. The results showed that miR-92a and miR-375 were downregulated while miR-134 was upregulated. MiR-92a and miR-375 had the highest diagnostic accuracy, with miR-375 being more specific. The findings suggest that miR-92a and miR-375 could serve as potential early biomarkers for AIS.